These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28128193)

  • 1. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
    Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
    Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].
    Yang X; Xue L; Guo L; Wen P; Lin D
    Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):243-53. PubMed ID: 24667263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.
    Lee JG; Kim S; Shim HS
    Lung Cancer; 2012 Jul; 77(1):156-61. PubMed ID: 22418245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDX-2 Expression in Primary Lung Adenocarcinoma.
    Cowan ML; Li QK; Illei PB
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
    Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
    Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
    Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
    Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Prognostic Value of ERCC1 and Thymidylate Synthase Expression and the Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma Non-Small-Cell Lung Cancer.
    Lin CS; Liu TC; Lai JC; Yang SF; Tsao TC
    Int J Med Sci; 2017; 14(13):1410-1417. PubMed ID: 29200955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
    Ke HG; Zhou XY; Shen Y; You QS; Yan Y; Shen ZY
    Oncol Res; 2012; 20(5-6):221-9. PubMed ID: 23581229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors.
    Koh Y; Kim DW; Kim TM; Lee SH; Jeon YK; Chung DH; Kim YW; Heo DS; Kim WH; Bang YJ
    J Thorac Oncol; 2011 May; 6(5):905-12. PubMed ID: 21358343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
    El Hag M; Schmidt L; Roh M; Michael CW
    Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry Profile Predicts
    Li W; Niehaus AG; O'Neill SS
    Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
    Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
    Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
    BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
    Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
    Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Characteristics of Napsin A, TTF 1 and EGFR Mutation Expression in Mucinous Lung Cell Carcinomas.
    Genova SN; Belovezhdov VT; Bichev SN; Danev VH
    Folia Med (Plovdiv); 2017 Jun; 59(2):174-182. PubMed ID: 28704186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.
    Zhang Z; Ye S; Zhang M; Wu J; Yan H; Li X; He J
    Tumour Biol; 2017 Jul; 39(7):1010428317720212. PubMed ID: 28720066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.